A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Conditions

• Symptomatic Genetic Dilated Cardiomyopathy

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• danicamtiv — DRUG
  Danicamtiv will be administrated twice daily for up to 26 weeks
• Placebo — DRUG
  Placebo will be administrated twice daily for up to 26 weeks

Study Details

The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM. The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM). The main goals of the study are: * To assess the effect of danicamtiv on cardiac function using echocardiogram. * To evaluate the impact of danicamtiv on exercise capacity * To evaluate the safety and tolerability of danicamtiv Participants will: * Take danicamtiv or placebo every day for approximately 6 months * Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up

Key Dates

Start date

Feb 13, 2026

Status verified

Mar 2026

Primary completion

Sep 30, 2027

Completion

Jan 31, 2028

Study Design

Enrollment

332 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: danicamtiv
• Placebo Comparator: placebo

Primary Outcome Measure

Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1 [ Time Frame: 26 weeks ]

Central Contacts

• Kardigan Clinical Trial Information Team
  1-877-310-5135
  [email protected]

Locations (18)

Find similar trials in Birmingham, AL